05.02.2024 22:11:28
|
Vertex Pharmaceuticals Inc. Q4 Profit Increases, beats estimates
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for its fourth quarter that increased from the same period last year and beat the Street estimates.
The company's earnings came in at $968.8 million, or $3.71 per share. This compares with $818.9 million, or $3.15 per share, in last year's fourth quarter.
Excluding items, Vertex Pharmaceuticals Inc. reported adjusted earnings of $1.10 billion or $4.20 per share for the period.
Analysts on average had expected the company to earn $4.10 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 9.6% to $2.52 billion from $2.30 billion last year.
Vertex Pharmaceuticals Inc. earnings at a glance (GAAP) :
-Earnings (Q4): $968.8 Mln. vs. $818.9 Mln. last year. -EPS (Q4): $3.71 vs. $3.15 last year. -Analyst Estimate: $4.10 -Revenue (Q4): $2.52 Bln vs. $2.30 Bln last year.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vertex Pharmaceuticals Inc.mehr Nachrichten
31.01.25 |
Schwacher Handel in New York: NASDAQ Composite schließt in der Verlustzone (finanzen.at) | |
31.01.25 |
Börse New York in Rot: S&P 500 notiert letztendlich im Minus (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 verbucht am Freitagnachmittag Gewinne (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: Pluszeichen im NASDAQ 100 (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: NASDAQ Composite-Börsianer greifen am Freitagnachmittag zu (finanzen.at) | |
31.01.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite-Anleger greifen zu (finanzen.at) | |
31.01.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 legt am Mittag zu (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 mit positivem Vorzeichen (finanzen.at) |
Analysen zu Vertex Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Vertex Pharmaceuticals Inc. | 444,40 | 5,26% |